Ibrahim Michel, Saint Croix Garly Rushler, Lacy Spencer, Chaparro Sandra
Division of Cardiovascular Medicine, Department of Medicine, Boston University Medical Center, Boston University School of Medicine, Boston, MA, USA.
Division of Cardiology at Mount Sinai Medical Center, Columbia University, Miami Beach, FL, USA.
Int J Heart Fail. 2020 Oct 20;3(1):69-77. doi: 10.36628/ijhf.2020.0030. eCollection 2021 Jan.
Renal dysfunction is a common comorbidity in patients with advanced heart failure who may benefit from left ventricular assist device (LVAD) therapy. The effect of preoperative renal dysfunction on clinical outcomes after LVAD implantation remains uncertain. We conducted a systematic review and meta-analysis to compare outcomes post-LVAD in patients with and without renal dysfunction.
PubMed, MEDLINE, and Embase databases were searched for studies comparing outcomes in patients with and without renal dysfunction who underwent LVAD implantation for advanced heart failure. The primary outcome of all-cause mortality was reported as random effects risk ratio (RR) with 95% confidence interval (CI).
Our search yielded 5,229 potentially eligible studies. We included 7 studies reporting on 26,652 patients. Patients with renal dysfunction (glomerular filtration rate [GFR] <60 mL/min/1.73 m) (n=4,630) had increased risk of all-cause mortality (RR, 2.21; 95% CI, 1.39-3.51; p<0.01) compared to patients with normal renal function (GFR >60 mL/min/1.73 m) (n=22,019).
Patients with renal dysfunction have increased mortality after LVAD implantation when compared to patients with normal renal function. GFR can be used to risk stratify patients and guide decision making prior to LVAD therapy.
肾功能不全是晚期心力衰竭患者常见的合并症,这些患者可能从左心室辅助装置(LVAD)治疗中获益。术前肾功能不全对LVAD植入术后临床结局的影响仍不确定。我们进行了一项系统评价和荟萃分析,以比较肾功能不全和肾功能正常的患者LVAD植入后的结局。
检索PubMed、MEDLINE和Embase数据库,查找比较因晚期心力衰竭接受LVAD植入的肾功能不全和肾功能正常患者结局的研究。全因死亡率的主要结局报告为随机效应风险比(RR)及95%置信区间(CI)。
我们的检索得到5229项潜在符合条件的研究。我们纳入了7项研究,共涉及26652例患者。与肾功能正常(肾小球滤过率[GFR]>60 mL/min/1.73 m²)(n=22019)的患者相比,肾功能不全(GFR<60 mL/min/1.73 m²)(n=4630)的患者全因死亡风险增加(RR,2.21;95%CI,1.39 - 3.51;p<0.01)。
与肾功能正常的患者相比,肾功能不全的患者LVAD植入后死亡率增加。GFR可用于对患者进行风险分层,并在LVAD治疗前指导决策。